Last Updated:
10 Mar 2026, 03:30:00 PM (IST)
Laurus Labs Limited
NSE: LAURUSLABS BSE: LAURUSLABS
NSE
1,038.00
17.00 (1.67%)
Prev Close
1021
Open Price
1030
Volume
1,367,251
Today Low / High
1030 / 1051.9
52 WK Low / High
517.65 / 1141
Range
986 - 1,090
BSE
1,037.30
16.40 (1.61%)
Prev Close
1020.9
Open Price
1022.8
Volume
53,408
Today Low / High
1021.15 / 1050.2
52 WK Low / High
517.05 / 1140.9
Range
985 - 1,089
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1038 (target range: 986 - 1,090), reflecting a change of 17 (1.66503%). On the BSE, it is listed at 1037.3 (target range: 985 - 1,089), showing a change of 16.4 (1.60643%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
02 Mar
1,030.00
3.40%
27 Feb
1,088.40
-1.16%
26 Feb
1,080.00
1.18%
25 Feb
1,035.00
4.00%
24 Feb
1,017.05
1.13%
23 Feb
1,024.40
-0.72%
20 Feb
1,021.20
-0.22%
19 Feb
1,044.80
-2.26%
18 Feb
1,019.00
1.81%
Laurus Labs Limited Graph
Laurus Labs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Laurus Labs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,038.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,037.30 | 1,047.67 | 942.91 - 1,152.44 |
| 1,058.05 | 846.44 - 1,269.66 | ||
| 1,068.42 | 747.89 - 1,388.94 | ||
| Bearish Scenario | 1,037.30 | 1,026.93 | 924.23 - 1,129.62 |
| 1,016.55 | 813.24 - 1,219.86 | ||
| 1,006.18 | 704.33 - 1,308.04 |
Overview of Laurus Labs Limited
ISIN
INE947Q01028
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,700,536
Market Cap
574,947,259,830
Last Dividend
0.8
Official Website
IPO Date
2016-12-19
DCF Diff
1,101.28
DCF
-36
Financial Ratios Every Investor Needs
Stock Dividend of LAURUSLABS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-10-31 | October 31, 25 | 0.8 | 0.8 | 2025-10-31 | 2025-11-12 | |
| 2025-05-09 | May 09, 25 | 0.8 | 0.8 | 2025-05-09 | 2025-05-20 | |
| 2024-11-06 | November 06, 24 | 0.4 | 0.4 | 2024-11-06 | 2024-11-23 | |
| 2024-05-08 | May 08, 24 | 0.4 | 0.4 | 2024-05-08 | 2024-05-25 | |
| 2023-10-30 | October 30, 23 | 0.4 | 0.4 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 5,553.96 Cr | 2,588.71 Cr | 2,965.25 Cr | 0.5339 | 55.30 Cr | 723.08 Cr | 2,173.09 Cr | 358.32 Cr | 6.65 | 1,034.19 Cr | 0.0645 |
| 2024-03-31 | 5,040.83 Cr | 2,539.79 Cr | 2,501.04 Cr | 0.4962 | 43.76 Cr | 642.19 Cr | 1,804.41 Cr | 160.55 Cr | 2.98 | 762.86 Cr | 0.0318 |
| 2023-03-31 | 6,040.55 Cr | 2,859.78 Cr | 3,180.77 Cr | 0.5266 | 25.59 Cr | 582.94 Cr | 2,555.64 Cr | 790.11 Cr | 14.69 | 1,605.93 Cr | 0.1308 |
| 2022-03-31 | 4,935.57 Cr | 2,248.82 Cr | 2,686.75 Cr | 0.5444 | 29.47 Cr | 503.84 Cr | 2,152.95 Cr | 827.52 Cr | 15.42 | 1,417.71 Cr | 0.1677 |
| 2021-03-31 | 4,813.51 Cr | 2,199.03 Cr | 2,614.48 Cr | 0.5432 | 17.29 Cr | 436.12 Cr | 2,159.18 Cr | 983.58 Cr | 18.36 | 1,549.78 Cr | 0.2043 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 99.54 Cr | 9,335.57 Cr | 4,733.05 Cr | 4,472.5600 Cr | 2,763.73 Cr | 2,619.52 Cr | 1,936.54 Cr | 4,315.96 Cr | 47.59 Cr | 347.60 Cr | 233.26 Cr | 3,539.7200 Cr |
| 2024-03-31 | 138.94 Cr | 8,387.03 Cr | 4,271.46 Cr | 4,110.9500 Cr | 2,577.40 Cr | 2,438.46 Cr | 1,845.41 Cr | 4,047.53 Cr | 81.85 Cr | 105.95 Cr | 123.98 Cr | 3,112.2800 Cr |
| 2023-03-31 | 45.67 Cr | 7,660.40 Cr | 3,611.74 Cr | 4,037.5300 Cr | 2,015.09 Cr | 1,969.42 Cr | 1,684.81 Cr | 3,700.17 Cr | 277.42 Cr | 125.50 Cr | 49.90 Cr | 2,432.2600 Cr |
| 2022-03-31 | 75.35 Cr | 6,968.04 Cr | 3,608.99 Cr | 3,351.1900 Cr | 1,776.66 Cr | 1,701.31 Cr | 1,760.30 Cr | 3,208.56 Cr | 616.06 Cr | 67.03 Cr | 62.78 Cr | 2,681.0100 Cr |
| 2021-03-31 | 48.46 Cr | 5,750.69 Cr | 3,149.99 Cr | 2,597.5500 Cr | 1,481.69 Cr | 1,433.23 Cr | 1,575.45 Cr | 2,277.17 Cr | 222.68 Cr | 71.84 Cr | -35.35 Cr | 2,457.1500 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 601.6500 Cr | -681.7200 Cr | 39.2800 Cr | -39.3500 Cr | -39.4000 Cr | 99.5400 Cr | -641.0000 Cr | 358.3200 Cr | 187.0700 Cr | -43.1300 Cr | -82.8600 Cr |
| 2024-03-31 | 665.6900 Cr | -822.4200 Cr | 249.8300 Cr | -12.6200 Cr | 93.2700 Cr | 138.9400 Cr | -678.3100 Cr | 160.5500 Cr | 541.0500 Cr | -86.1800 Cr | -151.3100 Cr |
| 2023-03-31 | 993.9000 Cr | -996.0600 Cr | -26.6400 Cr | 3.7400 Cr | -29.6800 Cr | 45.6700 Cr | -990.1600 Cr | 1,108.9400 Cr | 221.6200 Cr | -107.4700 Cr | 81.8300 Cr |
| 2022-03-31 | 911.1000 Cr | -914.3400 Cr | 30.2600 Cr | 34.2600 Cr | 26.8900 Cr | 75.3500 Cr | -876.8400 Cr | 1,083.8500 Cr | 270.2400 Cr | -85.8600 Cr | -174.3300 Cr |
| 2021-03-31 | 733.0000 Cr | -940.9900 Cr | 254.7000 Cr | 44.2300 Cr | 46.7700 Cr | 48.4600 Cr | -688.7700 Cr | 1,301.1100 Cr | 391.0700 Cr | -75.0400 Cr | -660.1700 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 1,778.29 Cr | 1,044.43 Cr | 733.86 Cr | 0.4127 | 359.59 Cr | 251.66 Cr | 4.66 | 485.97 Cr | 0.1415 |
| 2025-09-30 | 1,653.47 Cr | 999.49 Cr | 653.98 Cr | 0.3955 | 282.77 Cr | 194.97 Cr | 3.61 | 430.22 Cr | 0.1179 |
| 2025-06-30 | 1,569.57 Cr | 637.35 Cr | 932.22 Cr | 0.5939 | 717.42 Cr | 163.02 Cr | 3.02 | 367.54 Cr | 0.1039 |
| 2025-03-31 | 1,720.30 Cr | 893.41 Cr | 826.89 Cr | 0.4807 | 576.55 Cr | 233.67 Cr | 4.34 | 412.42 Cr | 0.1358 |
| 2024-12-31 | 1,415.05 Cr | 610.15 Cr | 804.90 Cr | 0.5688 | 615.78 Cr | 92.30 Cr | 1.71 | 271.06 Cr | 0.0652 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 63.38 Cr | 0.00 Cr | 63.38 Cr | 1,860.97 Cr | 2,020.96 Cr | 4,191.50 Cr | 4,518.74 Cr | 9,415.25 Cr | 4,481.72 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 144.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -4,602.52 Cr |
| 2025-03-31 | 50.64 Cr | 0.00 Cr | 50.64 Cr | 2,040.92 Cr | 1,738.88 Cr | 4,006.78 Cr | 4,315.96 Cr | 9,335.57 Cr | 4,733.05 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 44.92 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -4,144.16 Cr |
| 2024-09-30 | 44.92 Cr | 0.00 Cr | 44.92 Cr | 1,750.76 Cr | 2,107.13 Cr | 4,119.71 Cr | 4,094.02 Cr | 8,729.28 Cr | 4,585.12 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 163.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 233.67 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 92.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 19.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 12.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2020-09-29 | September 29, 20 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Executive Director of Quality & Executive Director
Lakshmana Rao Venkata Chunduru
Gender: Not Specified
Year Born: 1962
CEO & Whole Time Director
Satyanarayana Chava
Gender: Not Specified
Year Born: 1961
President of Manufacturing and Operations
V. R. K. Suryadevara Srinivasa Rao
Gender: male
Year Born: 1968
Executive Vice President of Finance
Chagarlamudi Sita Ramaiah
Gender: male
Year Born: 1973
Vice President of Legal, Compliance Officer & Company Secretary
Gogireddy Venkateswar Reddy
Gender: male
Year Born:
Executive Director of Synthesis & Executive Director
Krishna Chaitanya Chava
Gender: male
Year Born: 1990
Executive Vice President of Human Resources
Narasimha Rao Chava
Gender: male
Year Born: 1968
Senior Vice President of Generics
Nurubasha Babchand
Gender: male
Year Born: 1976
Executive Vice President of Manufacturing
Srinivasa Rao Suryadevara
Gender: male
Year Born: 1963
Chief Financial Officer & Whole-Time Director
Vantaram Venkata Ravi Kumar in Mgmt.
Gender: male
Year Born: 1965
FAQs about Laurus Labs Limited
Who is the CEO of the company?
The CEO is Satyanarayana Chava.
What is the current market price of the stock?
The current price is ₹1,065.00.
What is the 52-week price range?
The range is ₹517.65-1141.
What is the market capitalization of the company?
The market capitalization is ₹57,494.73 crores.
What is the dividend yield?
The dividend yield is 0.15%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 68.18.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Laurus Labs Limited (ISIN: INE947Q01028) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹57,494.73 crores and an average daily volume of 1,700,536 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.8.